Opinion|Videos|July 16, 2024
Examining the use of PD-L1 and tTMB in the CASPIAN Trial
Key opinion leaders examine the PD-L1 expression and tissue tumor mutational burden (TMB) data from the CASPIAN trial, which evaluated the combination of durvalumab with platinum-etoposide for extensive-stage small cell lung cancer (ES-SCLC), weighing the potential predictive value of PD-L1 and tissue TMB in assessing progression-free survival (PFS) and objective response rate (ORR) outcomes.
Advertisement
Episodes in this series
- Please discuss the PD-L1 expression and tissue TMB data from the CASPIAN trial evaluating durvalumab + platinum-etoposide for extensive-stage small cell lung cancer(ES-SCLC). (Paz-Ares L, et al. Clin Cancer Res. 2024; 30:824-835.)
- Importance or non-importance of PD-L1 and tissue TMB in predicting PFS and ORR.
- The potential OS benefit of adding tremelimumab to durvalumab + EP in patients with a PD-L1 expression of >1%.
- [Q4W vs single dose tremelimumab]
- In your expert opinion, is there value in combining the tTMB score and PD-L1 expression level as predictive biomarkers of therapeutic response?
- How might ctDNA methylation overcome the limitations of tissue-based biomarker assessment in better classifying both transcription factor-driven and independent SCLC subtypes?
- How could further refinement of this technique facilitate the initial diagnosis of SCLC, rapid therapy initiation, and liquid-biopsy-guided surveillance throughout treatment?
- Please elaborate on how aspects of an inflamed, tumor microenvironment might foster greater therapeutic response to immune checkpoint blockade.
- Epithelial mesenchymal transition (EMT) status
- Expression of: T cell attractant chemokines CCL5 and CXCL10
- CD8A and CD8B, which suggests greater cytotoxic T cell infiltration and cytolytic activity
- Interferon-γ related T cell gene expression profile (GEP)
- Bruton’s tyrosine kinase
Advertisement
Related to this article
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Daiichi Sankyo and Merck withdrew the I-DXd BLA in ES-SCLC after FDA discussions found phase 2 IDeate-Lung01 data insufficient for accelerated approval.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
China's NMPA Approves Pirtobrutinib Across CLL
2
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
Calculating the Real Cost of False Positive Findings in Cancer Screening
5